164 related articles for article (PubMed ID: 28817187)
21. Second line treatment options for pancreatic cancer.
Passero FC; Saif MW
Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
23. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Ueno M
Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
26. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
28. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Kieler M; Unseld M; Bianconi D; Scheithauer W; Prager GW
Ther Adv Med Oncol; 2019; 11():1758835919853196. PubMed ID: 31360237
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Macchini M; Orsi G; Militello A; Briccolani A; Falconi M; Cascinu S
Dig Liver Dis; 2024 Mar; 56(3):509-513. PubMed ID: 37586911
[TBL] [Abstract][Full Text] [Related]
30. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
33. Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
Sarfraz H; Saha A; Jhaveri K; Kim DW
Curr Oncol; 2023 May; 30(6):5322-5336. PubMed ID: 37366887
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
35. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.
Kasuga A; Hamamoto Y; Takeuchi A; Kawasaki K; Suzuki T; Hirata K; Sukawa Y; Takaishi H; Kanai T
Cancer Chemother Pharmacol; 2017 Mar; 79(3):595-602. PubMed ID: 28236000
[TBL] [Abstract][Full Text] [Related]
36. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
Woo W; Carey ET; Choi M
Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
[TBL] [Abstract][Full Text] [Related]
37. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.
Nagrial AM; Chin VT; Sjoquist KM; Pajic M; Horvath LG; Biankin AV; Yip D
Crit Rev Oncol Hematol; 2015 Dec; 96(3):483-97. PubMed ID: 26481952
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities.
Jain A; Bhardwaj V
World J Gastroenterol; 2021 Oct; 27(39):6527-6550. PubMed ID: 34754151
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis.
Kang MJ; Li HX; Gan Y; Fang C; Yang XL; Li B; Su S
Heliyon; 2024 Apr; 10(8):e27679. PubMed ID: 38681566
[TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
